{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-24-000122","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.482395+00:00","generated_at":"2026-05-30T03:26:41.784694+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cartesian Q3 net loss $(24.2)M; cash $220.9M; Phase 3 Descartes-08 in MG expected 1H2025","bullets":["Cash and equivalents $220.9M as of Sep 30, 2024; runway expected into mid-2027.","Net loss $(24.2)M ($(1.13)/share) vs $(9.0)M ($(1.74)) in Q3 2023.","Research and development expenses $11.4M, down from $13.0M year-over-year.","Plan to commence Phase 3 trial of Descartes-08 in myasthenia gravis in 1H2025 after FDA meeting.","Completed $130M PIPE financing in July 2024; first patient dosed in Phase 2 SLE trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-24-000122","json":"https://secwatch.observer/filing/0001453687-24-000122.json","markdown":"https://secwatch.observer/filing/0001453687-24-000122.md","text":"https://secwatch.observer/filing/0001453687-24-000122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000122/0001453687-24-000122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000122/rnac-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:26:41.784694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}